cyclosporin A microemulsion / Generic mfg. - LARVOL DELTA

Outcomes of Sirolimus vs Tacrolimus After Allogeneic Stem Cell Transplantation Using Mycophenolate/Post-Transplant Cyclophosphamide Conditioning (HOPA 2026) - "Calcineurin inhibitors (CNIs), such as cyclosporine A (CsA) and tacrolimus, have traditionally formed the backbone of immunosuppressive therapy in this context... The nonmyeloablative conditioning regimen consisted of fludarabine administered on days −6 through −2 and cyclophosphamide given on day −6 with mesna support, followed by total body irradiation delivered on day −1, with stem cell infusion occurring on transplant day 0. For GVHD prophylaxis, PTCy was administered on days +3 and +4, after which sirolimus and mycophenolate mofetil were initiated on day +5...Leukopenia remained the main adverse event but was generally controllable. Next step is evaluating tacrolimus within the same framework to compare safety and engraftment outcomes more directly."

Post-transplantation • Dyslipidemia • Graft versus Host Disease • Hematological Disorders • Immunology • Leukopenia • Thrombocytopenia • Transplantation

Pediatric Vernal Keratoconjunctivitis (VKC): Current State and Future Directions-A Narrative Review of Clinical Features, Diagnostic Strategies, and Emerging Therapies. (PubMed, Children (Basel)) - "We examined the immunological mechanisms that make it a model of localized Th2 inflammation, the diagnostic pitfalls that delay recognition, and the evolving treatment landscape, from conventional therapies like cyclosporine A and tacrolimus to innovative agents such as omalizumab and dupilumab. As research continues to expand our understanding, VKC is emerging as a prime example of how personalized medicine and translational science can intersect to address complex immune-mediated diseases in children. For the ones treating pediatric allergic disorders, VKC is no longer a rare curiosity: it is a clinical challenge worth understanding deeply."

Journal • Review • Allergy • Conjunctivitis • Corneal Abrasion • Dry Eye Disease • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov) - P2 | N=40 | Active, not recruiting | Sponsor: Boston Children's Hospital | Trial primary completion date: Jul 2026 ➔ Dec 2026

Trial primary completion date • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Transplantation • DKC1 • HLA-B • HLA-C • HLA-DRB1 • RTEL1 • TERT • ZCCHC8

Activating Inflammation Resolution Programs Improves Immunosuppressive Therapy and Prevents Toxicity in Autoimmune Bone Marrow Failure (IMMUNOLOGY 2026) - "Patients treated with cyclosporine A (CsA) exhibit sustained inflammation, frequent relapse, and secondary complications... CsA impairs inflammation resolution and long-term organ function. Co-treatment with RvE1 restores immune and hematopoietic homeostasis, supporting integration of pro-resolving therapy with IST for safer, durable remission for autoimmune and inflammatory diseases."

Aplastic Anemia • Hematological Disorders • Immunology • Inflammation

The Postnatal Lung Maturation Disrupted by Increased Pulmonary Blood Flow and Its Clinical Implications. (PubMed, JACC Asia) - "This study establishes the first neonatal IPF model and identifies actionable therapeutic targets, including immune modulators (NLRP3/IL23R inhibitors), cell cycle regulators (Birc5/CENPE agonists), and neural/circadian mediators (Nr1d1/Per2 activators). These findings provide a roadmap for mitigating IPF-driven lung maldevelopment."

Journal • Cardiovascular • Heart Failure • Hypertension • Idiopathic Pulmonary Fibrosis • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • BIRC5 • NLRP3 • NR1D1 • PER2

Transcriptomic Analysis of Adipose-Derived Stem Cell Therapy Modulating B Cell Immune Tolerance in Vascularized Composite Allotransplantation. (PubMed, Plast Reconstr Surg) - "ADSC-based therapy combined with short-term immunosuppression promotes immune tolerance in VCA by modulating B cell-related gene expression. These findings suggest that targeting B cell-mediated pathways may provide a novel approach may offer a novel therapeutic strategy for clinical application in VCA."

Journal • Transplantation • CXCL1 • SIGLEC5 • TLR3

Dual Mechanisms of Morin in Bioavailability Potentiation and Hepatoprotection: Enhancing Enrofloxacin Safety in Poultry through ABC Transporter Inhibition and Antioxidant Pathway Activation. (PubMed, Vet J) - "However, earlier-generation ABC transporter inhibitors, such as verapamil and cyclosporine A, are limited by inherent hepatotoxicity. Furthermore, morin effectively alleviated enrofloxacin-LPS-induced DILI through activation of the Nrf2-mediated antioxidant pathway and suppression of the NF-κB-mediated inflammatory response. In conclusion, morin functions as a novel dual-functional oral enhancer that not only boosts enrofloxacin bioavailability by inhibiting ABC transporters and downregulating their CXR-mediated expression but also confers hepatoprotection via the Nrf2/NF-κB pathways, thereby presenting a viable strategy to combat the AMR while ensuring drug safety in poultry production."

Journal • Hepatology • Inflammation • Liver Failure

HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN NEUROPATHIC MUCOPOLYSACCHARIDOSIS TYPE-II (MPS-II) PRESERVES NEURODEVELOPMENT AND SHOULD BE ROUTINE PRACTICE (EBMT 2026) - "He was conditioned with Busulfan and Fludarabine following the standard European Guidelines...The same donor donated PBSC and conditioning was with Fludarabine, Thiotepa and Treosulfan. Alemtuzumab serotherapy, Cyclosporin-A and mycophenolate mofetil used as GVHD prophylaxis. Defibrotide was used for VOD prophylaxis in second transplant due to experiencing mild VOD during first transplant.Multisystem evaluation including neurodevelopmental assessments were recorded over 6–7 follow-up-years... In neuropathic MPS-II, definitive therapy with HSCT in early infancy preserves neurodevelopment and significantly reduces the multi-system disease burden compared with initiating ERT in later childhood. This sibling case-comparison supports the rationale for the need of newborn screening and prompt referral for HSCT. We have separately developed a gene therapy programme to further improve outcomes of cellular therapy in MPS-II and are reporting those outcomes at this meeting."

Bone Marrow Transplantation • CNS Disorders • Gene Therapies • Graft versus Host Disease • Hunter Syndrome • Hurler Syndrome • Immunology • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases • Transplantation

HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCIES IN CHILDREN: THE UKRAINIAN EXPERIENCE (2018–2025) (EBMT 2026) - "GVHD prophylaxis was donor-adapted: matched sibling donors (MSD) received cyclosporine A (CsA) and methotrexate (MTX); matched unrelated donors (MUD) received CsA, MTX, and antithymocyte globulin (ATG); haploidentical donors received post-transplant cyclophosphamide (PTCy), CsA, and mycophenolate mofetil (MMF)...Importantly, five SCID cases were identified through the national newborn screening program, enabling pre-symptomatic diagnosis and early referral for transplantation.Twenty-two patients received treosulfan-based conditioning; one received melphalan, and two neonatally screened infants underwent HCT without conditioning... Allogeneic HCT is a feasible and effective curative strategy for children with PIDs in Ukraine, achieving high overall survival and low early transplant-related mortality. The implementation of a national expanded newborn screening program enabled earlier identification of SCID and timely transplantation, contributing to improved outcomes...."

Clinical • Acute Graft versus Host Disease • Cardiovascular • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Metabolic Disorders • Primary Immunodeficiency • Transplantation

63 HLA-IDENTICAL RELATED HAEMOTOPOIETIC STEM CELL TRANSPLANTS IN SICKLE CELL DISEASE (EBMT 2026) - "Since 2015, hydroxyurea was initiated/intensified 1 month before to keep reticulocytes <100,000/mm³...Ovarian tissue is cryopreserved since 2015.Conditioning regimen:Until January 2015: Busulfan, cyclophosphamide, alemtuzumab. Graft versus host disease (GVHD) prophylaxis: cyclosporine A (CsA) and methotrexate.After January 2015: Thiotepa, Treosulfan, Fludarabine, anti-thymocyte globulin (myeloablative conditioning but reduced toxicity).GVHD prophylaxis: CsA, mycophenolate mofetil (MMF) (Jan 2015–Feb 2019); tacrolimus, MMF (Feb 2019–May 2024) or tacrolimus, MMF and post-transplant cyclophosphamide (PTCy) (January 2025–May 2025).Epidemiological, clinical, and analytical parameters were collected... The results of our study, the largest HSCT series in Spain, is similar to the international cohort and confirms the role of HSCT for children with SCD . Long-term follow-up remains essential to identify late complications."

Acute Graft versus Host Disease • Acute Kidney Injury • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • CNS Disorders • Epilepsy • Gene Therapies • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Hypertension • Immunology • Lymphoma • Sickle Cell Disease • Subarachnoid Hemorrhage • Transplantation

RESULTS OF ALLOGENEIC HSCT IN CR1 FOR PEDIATRIC PATIENTS WITH DE NOVO, HIGH-RISK, ACUTE MYELOID LEUKEMIA (AML): A REPORT FROM AIEOP (EBMT 2026) - "The recommended conditioning regimen was busulfan+cyclophosphamide+melphalan in case of transplant from an HLA-matched donor, while for mMUD or PMFD conditioning was chosen by the treating physician. GvHD prophylaxis consisted of short-course methotrexate and cyclosporine-A; serotherapy (Grafalon 5 mg/kg/day for 3 days) was added in patients transplanted from an unrelated donor... These data confirm improvement in transplant technique in recent years, as supported by the low incidence of NRM, and indicate that allo-HSCT is an efficacious option for consolidation of pediatric patients with HR AML."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pediatrics • Septic Shock • CBFA2T3 • CD34 • FLT3 • GLIS2 • KMT2A • NUP98

ROLE OF PHARMACOGENETICS IN THE EFFICACY OF LOW-DOSE METHOTREXATE ADMINISTERED AS GVHD PROPHYLAXIS IN PEDIATRIC ALL PATIENTS: A FORUM STUDY (EBMT 2026) - P2/3, P4 | "Clinical Trial Registry: NCT01949129, NCT02670564 Background: Methotrexate (MTX) is commonly used as acute graft versus host disease (aGvHD) prophylaxis in combination with cyclosporine A (CsA) following hematopoietic stem cell transplantation (HSCT) in pediatric acute lymphoblastic leukemia (ALL) patients. Our candidate gene approach validated the recipient MTHFR A1298C variant as a significant determinant of MTX prophylaxis efficacy against aGvHD in a homogenous cohort of children with ALL undergoing HSCT from HLA 9-10/10 matched donors. Elucidating the regulatory mechanism of the folate pathway may help personalize MTX administration for post HSCT GvHD prophylaxis."

Biomarker • Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Pediatrics • MTHFR

DONOR SELECTION AND CLINICAL OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS OLDER THAN 50 YEARS - A SINGLE CENTRE RETROSPECTIVE REVIEW (EBMT 2026) - "While matched sibling donors (MSD) have traditionally been considered standard, the benefits of younger alternative donors and the impact of post-transplantation cyclophosphamide (PTCy) prophylaxis remain unclear in this population...Patients received either PTCy-based (40mg/kg/day on days +3 to +4 with cyclosporine A and mycophenolate mofetil) or conventional calcineurin inhibitor-based graft-versus-host-disease (GVHD) prophylaxis... In patients > 50 years old, MUD allo-HSCT with younger donors and conventional GVHD prophylaxis achieved outcomes comparable with those of older MSD allo-HSCT. Notably, haploidentical allo-HSCT with PTCy demonstrated superior RFS and GRFS compared with MSD allo-HSCT with conventional GVHD prophylaxis, suggesting that alternative donor approaches with optimized GVHD prophylaxis might be advantageous in this older population. Disease risk index remained an important independent predictor of outcomes in all donor types."

Clinical data • Retrospective data • Review • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation

CUMULATIVE CYCLOSPORINE A EXPOSURE AND LONG-TERM OUTCOMES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA (EBMT 2026) - "Higher cumulative CsA exposure in the first 100 days after alloHCT, was associated with markedly improved OS and RFS and less cGvHD, independent of disease risk. These findings suggest that, in contrast to concerns derived from solely trough-based monitoring, greater cumulative exposure within standard therapeutic ranges was not associated with less GvL activity."

Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

MANAGEMENT OF PROTRACTED CLOSTRIDIOIDES DIFFICILE INFECTION IN CHILDREN WITH GI-GVHD AFTER ALLOGENEIC HSCT: A SINGLE-CENTER PEDIATRIC EXPERIENCE (EBMT 2026) - "According to ECIL-10 recommendations, bezlotoxumab and fecal microbiota transplantation (FMT) may be considered in recurrent CDI after vancomycin or fidaxomicin therapy in high-risk patients...Persistent CDI was documented from day +55 despite intensive immunosuppression (cyclosporine A, corticosteroids, ruxolitinib, mesenchymal stromal cells, extracorporeal photopheresis, vedolizumab)...TA-TMA was confirmed and treated with ravulizumab... Management of CDI after allo-HSCT requires a comprehensive and highly individualized approach, as CDI frequently coexists with GI-GvHD and TA-TMA. CDI may exacerbate GI-GvHD, while immunosuppression increases infection severity. Protracted CDI can lead to long-lasting intestinal dysfunction requiring supportive interventions, including teduglutide."

Clinical • Bone Marrow Transplantation • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Infectious Disease • Pediatrics • Septic Shock • Transplantation Associated Thrombotic Microangiopathy

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A POLISH PEADIATRIC EXPERIENCE (EBMT 2026) - "Conditioning regimens included treosulfan, fludarabine, melphalan and alemtuzumab. Graft-versus-host disease (GvHD) prophylaxis consisted of methotrexate, tacrolimus or cyclosporine A. Both patients had prolonged, treatment-resistant disease with multi-joint involvement despite extensive therapy, including glucocorticosteroids, immunosuppressants, and multiple biologics... AlloHSCT may represent a feasible and effective therapeutic option for selected pediatric patients with refractory arthritis syndromes who fail to respond to pharmacotherapy. In this small cohort, the procedure resulted in meaningful clinical improvement and enhanced quality of life. Nevertheless, the risks of transplant-related complications must be weighed against potential benefits, and long-term follow-up is essential to fully assess the durability of remission."

Clinical • Bone Marrow Transplantation • Graft versus Host Disease • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Mucositis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Rheumatology • Transplantation

IMPACT OF RECIPIENT AGE AND CYCLOSPORIN A TARGET LEVEL ON MIXED CHIMERISM AFTER TREOSULFAN-BASED MATCHED FAMILY DONOR HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE (EBMT 2026) - "All patients received reduced-toxicity protocols (RTPs), which were predominantly treosulfan-fludarabine-thiotepa-based (69.9%). Four-year OS and GSFS did not differ significantly between conditioning regimens (treosulfan-based: 97.1% and 82.8%; busulfan-based: 95.2% and 89.2%; melphalan-based: 100.0% and 77.8%)...This corresponded to a faster reduction (median day: Thymoglobulin® 73, ATG-Fresenius 124 (p<0.001)) and discontinuation (Thymoglobulin® 115, ATG-Fresenius 162 (p<0.001)) of calcineurin inhibitors in this subgroup... The results of our detailed, multicentre data analysis confirm excellent OS across all donor types, but significantly better GSFS after MFD HSCT for SCD. We identified risk factors (Thymoglobulin®, CSA≥150µg/l, age<6 years, reduced myeloablation) for the development of MC in treosulfan-based conditioning regimens. These data should assist in risk-adapted optimization of RTPs especially in the setting of MFD-HSCT."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Sickle Cell Disease • Transplantation

FROM IMMUNODEFICIENCY TO MALIGNANCY: SUCCESSFUL ALLOGENEIC HSCT IN NIJMEGEN BREAKAGE SYNDROME WITH LATE RELAPSE T-ALL (EBMT 2026) - "Graft-versus-host disease (GVHD) prophylaxis consisted of post-transplant cyclophosphamide, cyclosporine A and mycophenolate mofetil. This case illustrates the feasibility and efficacy of allo-HSCT in a young adult with NBS, achieving simultaneous treatment of combined immunodeficiency and high-risk relapsed T-ALL. Given the very high risk of haematological malignancies in NBS, early consideration of allo-HSCT at the stage of confirmed immunodeficiency, before malignant transformation, may be warranted. Multicentre studies are needed to define optimal indications, timing and transplant strategies in this rare but high-risk population."

Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Metabolic Disorders • Oncology • Primary Immunodeficiency • Respiratory Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Thrombocytopenia • ABL1 • BCR • CDKN2A • ETV6 • IKZF1 • MECOM • NBN • PBX1 • RUNX1 • TP53

OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS WITH PERI-TRANSPLANT-RUXOLITINIB PROPHYLAXIS (EBMT 2026) - "Pre-alloHCT treatments included ruxolitinib (73.5%), hydroxyurea (42.6%) and supportive therapies (17.6%, e.g erythropoietin, anagrelide and phlebotomy). All patients received peripheral blood stem cell grafts, mostly from 10/10 matched unrelated donors (MUD, 67.7%) (Table 1) after conditioning with fludarabine, thiotepa and melphalan (FTM, 44.1%), fludarabine, carmustin and melphalan (FBM, 30.9%) or thiotepa, fludarabine and treosulfan (TFTreo, 25.0%). GvHD prophylaxis consisted of a backbone of cyclosporine A (CsA) + mycophenolate (MPA) in 85.3% or everolimus + MPA in 14.7% of patients and was combined with serotherapy (anti-T-lymphocyte globulin (ATLG) or alemtuzumab) in 80.9% of cases.Prevalence of GvHD requiring systemic treatment (acute GvHD (aGvHD) or chronic GvHD (cGvHD)) was 50.0% in the entire cohort (with ruxolitinib: 28.6%, without ruxolitinib: 55.6%) and distributed equally between aGvHD (overall: 36.8%, with ruxolitinib: 28.6%, without ruxolitinib: 35.2%)..."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Myelofibrosis • Transplantation • CALR • JAK2

PAROUS FEMALE DONOR REDUCES RELAPSE RISK IN HIGH-RISK AML/MDS AFTER HAPLOIDENTICAL PBSCT WITH ATG/PTCY COMBINATION FOR GVHD PROPHYLAXIS (EBMT 2026) - "However, the combination of low-dose anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) has shown promising efficacy in preventing GVHD following haploidentical peripheral blood stem cell transplantation (haplo-PBSCT)...The low-dose ATG/PTCy regimen consisted of ATG (2.5 mg/kg/day on days -2 to -1), PTCy (50.0 mg/kg/day on day +3), cyclosporine A (CsA), and mycophenolate mofetil (MMF) (initiated on day +4)... These findings suggest that the parous female donor may provide enhanced relapse protection without increasing NRM in AML/MDS patients receiving ATG/PTCy-based haplo-PBSCT."

Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome

HAPLOIDENTICAL SCT INDUCES LONG-TERM REMISSION IN PATIENTS WITH BPDCN (EBMT 2026) - "GvHD prophylaxis comprised cyclosporine A, MMF and short-term MTX, plus ATG (2.5mg/kg, days -5 to -2)... HID-SCT was feasible and with low TRM resulting in excellent survival in BPDCN patients, even in no-remission patients. No one relapsed in this cohort, and this demonstrated the stronger GVT effect and long-term diseased control of HID-SCT in BPDCN patients."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia

CYTOMEGALOVIRUS CELL-MEDIATED IMMUNITY GUIDED LETERMOVIR PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL (EBMT 2026) - P3 | "Letermovir was given orally or intravenously at a dose of 480 mg daily from day 1, or 240 mg daily when in conjunction with cyclosporine A. CMV-CMI was evaluated with CMV-ELISPOT at at the 3rd, 5th, 6th, and 9th month post-HCT. The CMV-CMI-guided strategy of letermovir use for CMV prophylaxis after allo-HCT is effective and safe in reducing the cumulative incidence of late-onset cs-CMVi after letermovir withdrawal."

Clinical • P3 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

OLDER MATCHED SIBLING DONOR VS YOUNG HAPLOIDENTICAL DONOR FOR ALLOGENEIC TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN SECONDARY ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ALWP/EBMT (EBMT 2026) - "PTCy was most frequently combined with cyclosporine A /mycophenolate mofetil-based immunosuppression as graft-versus-host disease (GvHD) prophylaxis. Thiotepa/busulfan (Bu)/Fludarabine (Flu) was the most frequent conditioning in yHaplo pts, while it was Bu/Flu in the oMSD group... HSCT with PTCy for sAML in CR1, from yHaplo vs oMSD, resulted in similar transplantation outcomes, besides a higher incidence of NRM and slower neutrophil engraftment, while a lower incidence of ext cGvHD in the yHaplo compared to the oMSD."

Post-transplantation • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Transplantation

EARLY ALLOGENEIC TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN HIGH-RISK T-CELL LYMPHOMA: RESULTS OF A PROSPECTIVE PHASE 2 STUDY (EBMT 2026) - P=N/A | "Pts received myeloablative conditioning with BuCy, MeCCNU, and Ara-C or TBI (8 Gy). GVHD prophylaxis consisted of cyclosporine A, MMF, and short-term MTX, plus ATG (10mg/kg) for unrelated or haplo-transplants...The cumulative incidences of acute and chronic GVHD were 45.7% and 62.8%.Off-study pts: Eight of 9(no alloSCT) died of lymphoma, 1 keep CR with chidamide maitaining... Early alloSCT as 1st line consolidation was feasible in two-thirds of pts with low TRM resulting in excellent survival. All but one pts without alloSCT died of lymphoma. Notably, 40% of study pts suffered from HSTCL or MEITL."

Clinical • P2 data • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Immunology • Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation

AUTOLOGOUS UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT CHEMOTHERAPY-BASED CONDITIONING IN A CHILD WITH SEVERE APLASTIC ANEMIA: A CASE REPORT (EBMT 2026) - " Immunoablation was initiated with four doses of equine antithymocyte globulin (Atgam, 40 mg/kg), after which a substantial number of residual T lymphocytes was observed (818/µL). To intensify the immunoablation, the patient subsequently received a 3-day course of antithymocyte globulin (Grafalon, 5 mg/kg), followed by a 2-day course of antithymocyte globulin (Thymoglobulin, 3.75 mg/kg), administered with methylprednisolone and cyclosporine A. Subsequently, the child underwent auto-UCBT containing 0.13 × 10⁶ CD34+ cells/kg and continued treatment with cyclosporine A and prednisone... Early neutrophil recovery may indicate better underlying stem cell reserve, due to auto-UCBT infusion, though this interpretation remains speculative. Auto-UCBT after immunosuppression-based protocol appears to be a promising curative option for pediatric SAA patients with stored autologous cord blood and without available matched sibling. A key prerequisite for autoUCBT in SAA is..."

Case report • Clinical • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Transplantation • CD34